Florida Cancer Specialists & Research Institute Leadership Review of Step Therapy Policies Details Troubling Impacts to Cancer Patients

A review by Florida Cancer Specialists & Research Institute leaders says insurer step therapy and prior-authorization requirements can delay access to clinically recommended cancer treatments and create patient, provider and equity risks. In a cited survey, 69% of patients who experienced prior authorization reported care delays; nearly three-quarters of those delays lasted at least two weeks, and 22% said they did not receive recommended treatment because of authorization-related delays or denials. The authors call for rapid exceptions and appeals, continuity-of-care protections, transparent standards and lower administrative burdens, while noting that oncology-specific evidence remains limited.

Analysis

The investable signal is policy risk, not a newly measured deterioration in oncology outcomes: this is an advocacy-oriented literature review, and the authors themselves flag limited oncology-specific evidence. Near term, it is unlikely to change payer economics on publication alone. The more material path is a 1–3 month policy and employer response: if the findings are cited in legislation, regulator guidance, or large-employer contracting, utilization-management rules could face tighter exception timelines and continuity-of-care standards. That would reduce some administrative friction for community oncology, but could also shift payer cost control toward narrower networks, negotiated drug prices, or preferred biosimilars rather than eliminate it.

The potential winners are oncology practices with scale, centralized authorization teams, and clinical-trial alternatives; smaller practices face relatively greater labor and cash-flow friction when treatment starts are delayed. Drugmakers with biomarker-specific therapies could benefit if exceptions become easier, while payer-preferred products may lose some forced volume. This is not uniformly positive for branded oncology: payers can respond to weaker step edits with tougher price concessions or other controls. The company-authored review and survey figures are not a basis to quantify earnings sensitivity, and FCS is not publicly mapped in the supplied data.

Contrarian read: headlines about patient harm may overstate the odds of rapid, broad federal intervention. Fragmented rules and limited oncology-specific evidence make incremental, state-by-state change more plausible than a near-term reset of managed-care margins. Reassess if binding rules or major employer contracts measurably change authorization timelines or denial rates.

Key Decisions for Investors

• No immediate directional trade on this publication alone. Treat it as a low-conviction policy watch item, not evidence of near-term earnings revisions for health insurers or oncology drugmakers.
• Monitor state and federal proposals for oncology-specific exception deadlines, continuity-of-care protections, and appeal requirements over the next 1–3 months. Upgrade payer-margin risk only if proposals advance into binding rules or large employer contracts.
• For oncology drug exposure, track formulary and authorization changes alongside launch uptake: easier exceptions could support biomarker-directed branded therapies, but watch for offsetting price concessions and substitution toward payer-preferred biosimilars.
• Falsification: the thesis weakens if policy proposals stall and subsequent payer disclosures show no meaningful change in oncology authorization practices; it strengthens if denial rates, treatment-start delays, or administrative costs worsen in independently verifiable data.